📌 At a Glance
P&G Health Ltd (NSE: PGHL) just pulled off a rare feat — a 27% PAT growth in just 9 months, all while changing their fiscal year! From July–March, the company posted ₹918 crore in revenue and ₹234 crore in PAT, backed by strong brand plays like Neurobion and Livogen. Oh, and the board’s feeling generous — total dividend? ₹125/share.
🧬 Key Highlights
| 🔍 Metric | 9M FY25 (Jul–Mar) | YoY Growth |
|---|---|---|
| Revenue | ₹918 Cr | +8% |
| PAT | ₹234 Cr | +27% (14% adj. excl. one-time) |
| Dividend | ₹125/share | 🧨 Boom! |
- Q3 FY25 Revenue: ₹304 Cr (+23%)
- Q3 FY25 PAT: ₹61 Cr (+31%)
🧪 Why Only 9 Months?
Because P&G decided 12 months is too mainstream.
- Old FY: July to June
- New FY: April to March (aligned with Indian fiscal norms)
- FY25 was a transition year, covering July 1, 2024 – March 31, 2025
Comparison is made against the same period last year. Basically, FY25 is “9 to 5” with extra results.
🧾 Dividend Bonanza 💸
| Type | ₹/share |
|---|---|
| Interim | ₹80 |
| Final | ₹45 |
| Total | ₹125 |
- That’s a 2.15% yield on CMP of ₹5,800.
- Not bad for a pharma-VMS hybrid with a blue-chip DNA.
💊 What’s Driving the Growth?
- Brand Mojo: Neurobion, Livogen, Evion — still powering prescriptions and OTC shelves
- Strong Go-To-Market: Better retail footprint and digital physician engagement
- Supply Chain Tightening: Inventory and channel efficiency = higher margins
- Focused Strategy: Limited product range = high operational leverage
📈 Outlook & EduInvesting Take
P&G Health isn’t your typical pharma stock — it’s a steady, dividend-paying, brand-heavy machine riding on trust, not patents.
- They’re not launching 10 new molecules every year.
- They’re selling vitamins, minerals, supplements, and nasal sprays like it’s FMCG.
- And they’re doing it with precision.
Edu Verdict: In a world of biotech moonshots, this is your sip-your-vitamin-C-and-chill stock. Not multibagger territory, but a core portfolio candidate for stability and dividend lovers.
Also, full-year FY26 will likely look stronger as it won’t have that fiscal shortening quirk. Watch out for margin expansion if input costs ease.
Author: Prashant Marathe
Date: 29 May 2025
Tags: PGHL FY25 Results, Procter & Gamble Health Dividend, VMS Sector India, Pharma Earnings, High Dividend Stocks, Neurobion Sales Growth, Livogen Performance
